Supercede Therapeutics develops small molecule inhibitors targeting the Activin receptor Type II (ACTRII) kinase to promote significant fat loss while preserving lean body mass in patients with obesity. By utilizing bioinformatics and focused clinical development strategies, the company aims to expedite the drug discovery process and deliver effective therapies to those in need.
Funding
Funding not disclosed
Founders
Product
Problem
Current obesity treatments often result in the loss of both fat and lean muscle mass, which can have negative health consequences. Existing therapies may also rely on mechanisms that cause extreme appetite suppression, potentially leading to other adverse effects. There is a need for obesity treatments that selectively target fat loss while preserving or increasing lean body mass, and that offer alternative mechanisms of action.
Solution
Supercede Therapeutics is developing STX-001, a novel, oral small molecule inhibitor of the Activin receptor Type II (ACTRII) kinase, for the treatment of obesity. STX-001 is designed to selectively inhibit the ACTRII signaling pathway, which has been clinically demonstrated to reduce fat mass while preserving or increasing lean body mass. This approach aims to improve body composition in patients with obesity, either as a standalone therapy or in combination with incretin-based treatments like GLP-1 agonists. Supercede's compounds have shown oral bioavailability and in vivo activity in animal models, suggesting potential for a novel oral treatment option. The company utilizes bioinformatics and AI/ML to enhance drug discovery and focus clinical development strategies.
Target Audience
The primary target audience includes patients with obesity who need treatments that selectively reduce fat mass while preserving or increasing lean muscle mass, as well as clinicians seeking novel therapeutic options for their patients.
Features
- Oral small molecule inhibitor of the Activin receptor Type II (ACTRII) kinase
- Selective inhibition of ACTRII signaling to promote fat loss and preserve lean mass
- Potential for combination therapy with GLP-1 agonists
- Oral bioavailability and in vivo activity demonstrated in animal models
- Utilizes bioinformatics and AI/ML for efficient drug discovery